https://www.live-feeds.com/feed/astrazeneca-s-copd-drug-scores-two-late-stage-trial-wins-as-full-data-boosts-blockbuster-hopesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/astrazeneca-s-copd-drug-scores-two-late-stage-trial-wins-as-full-data-boosts-blockbuster-hopeshttps://www.live-feeds.com/feed/astrazeneca-s-copd-drug-scores-two-late-stage-trial-wins-as-full-data-boosts-blockbuster-hopes#u65773Sat, 12 Sep 2026 03:42:36 +0000AstraZeneca's IL-33 antibody Tozorakimab significantly reduced moderate and severe COPD exacerbations in the OBERON and TITANIA Phase 3 trials. The drug proved effective for patients who continued to suffer flare-ups despite using standard-of-care inhaled therapy. These results have earned the treatment priority review, though the company still faces unresolved questions regarding approval and launch economics. AstraZeneca R&D chief Barr described the outcome as an internal science success story, supporting the company's goal of creating a blockbuster treatment for chronic obstru https://www.live-feeds.com/feed/astrazeneca-s-copd-drug-scores-two-late-stage-trial-wins-as-full-data-boosts-blockbuster-hopeshttps://www.live-feeds.com/feed/astrazeneca-s-copd-drug-scores-two-late-stage-trial-wins-as-full-data-boosts-blockbuster-hopes#u62924Wed, 09 Sep 2026 17:03:37 +0000AstraZeneca reported that its IL-33 antibody, Tozorakimab, significantly reduced COPD exacerbations in two late-stage clinical trials named OBERON and TITANIA. The drug showed benefits across various patient groups, including current and former smokers. AstraZeneca R&D chief Barr described the results as an internal science success story. The company expects the full data to support its goal of creating a blockbuster treatment for chronic obstructive pulmonary disease by reducing lung disease flare-ups.Why it mattersCOPD is a chronic inflammatory lung disease that often leads to acute exac